Humacyte, Inc. (HUMA) — insider trading
Health Care · NASDAQ
Humacyte, Inc. (HUMA) has 12 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase among the most recent 12 (latest 2026-06-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-11 | Dougan Brady W | Director | Grant / award / vesting (derivative) | 0 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Brown Emery N. | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Bamforth John Philip | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Seimetz Diane | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Green Charles Bruce | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Jones Keith Anthony | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Sebelius Kathleen | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Niklason Laura E | Director, Officer (President, CEO and Director) | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Wallace Max N. | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Constantino Michael T. | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Windham-Bannister Susan Richards | Director | Grant / award / vesting (derivative) | 80,000 | $0.00 | $0 | Form 4 |
| 2026-05-19 | Sebelius Kathleen | Director | Open-market purchase | 56,818 | $0.88 | $50.0K | Form 4 |
Ask the chat about HUMA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Humacyte, Inc. (HUMA).
Last updated 2026-06-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.